Algazi A, Tsai K, Bannavong D, et al. Clinical immune monitoring and biomarker data of pIL-12 monotherapy compared to pIL-12 with pembrolizumab in metastatic melanoma supports the rationale for combination therapy. SMR 2017, abstract FC05-3.
PARP-remmers: een nieuw tijdperk in de behandeling van (recidiverende) ovariumkanker
aug 2020 | Gynaecologische oncologie